Abattis Announces Cancellation of 10,250,000 Shares Pursuant to Termination of ZITEK Licensing Agreement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 17, 2012) - Abattis Biologix Corporation (the "Company" or "Abattis") (CNSX:FLU) is pleased to announce that further to the termination of the Company's agreement with the Hensley Group Inc. (see the Company's news release of January 24, 2012), 10,250,000 common shares previously issued in relation to the agreement were surrendered to the Company and were cancelled and returned to treasury effective February 17, 2012.
Prior to the shares being surrendered the company had 61,937,900 issued and outstanding. The new issued and outstanding is 51,687,900.
About Abattis Biologix Corporation
Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The company has identified targeted channels to market and license proprietary patent pending products throughout the world.
ON BEHALF OF THE COMPANY
Yazan Al Homsi, Director

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.